2020 Speakers
World Orphan Drug Congress USA will feature 350+ speakers from pharma, biotechs, government, regulators, patient groups & service providers.
Rebecca Abbott, Office Of Government Affairs, March of Dimes Foundation
Thomas Abbott, Head, Real World Data And Evidence, Astellas Pharma
Younos Abdulsattar, US Vyndaqel Medical Team Lead, Rare Disease, Pfizer
Derek Adams, Chief Technology And Manufacturing Officer, bluebird bio
Sherilyn Adcock, Executive Vice President, Medical And Scientific Affairs, Worldwide Clinical Trials
Sonalee Agarwal, Vice President Of Value And Evidence Strategy, Alnylam Pharmaceuticals
Jeonghoon Ahn, Former Director, National Evidence-based Healthcare Collaborating Agency
Sean Ainsworth, Chief Executive Officer And Chairman, Immusoft Corporation
M Javad Aman, Chief Executive Officer, Integrated Biotherapeutics
Derek Ansel, Director, Rare, Orphan and Pediatric Diseases, Synteract
Kristin Anthony, President, Pten Hamartoma Tumor Syndrome Foundation
Anjan Aralihalli, Venture Partner, C.T.I. life Sciences Fund
Diego Ardigo, R&D Rare Diseases Unit Head, Chiesi Farmaceutici SpA
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy, NIHDI - INAMI Belgium
Rasappa Arumugham, Chief Scientific Officer, Ocugen
Rania Ashraf, Associate Director Market Access, Janssen
Kagan Atikeler, Researcher, Utrecht University
Christopher Austin, Director, National Center For Advancing Translational Sciences (Ncats), National Institutes of Health (NIH)
Mark Baglin, Vice President Of Global Marketing, Alnylam Pharmaceuticals
Lakiea Bailey, Executive Director, Sickle Cell Consortium
Annette Bakker, President, Childrens Tumor Foundation
Ron Bartek, President, Director, And Founder, Friedreich's Ataxia Research Alliance
Peter Bauer, Chief Genomic Officer, CENTOGENE US, LLC
Shannon Baumann, Senior Director, Access Value And Evidence Strategy, bluebird bio
Anny Bedard, Head Of International Business, Commercial Operations, Sarepta Therapeutics
Gregory Bell, Group Vice President And Life Sciences Practice Leader, Charles River Associates
Alon Ben-Noon, CEO, NeuroSense Therapeutics
Allyson Berent, Chief Operating Officer, Genetx Biotherapeutics, Chief Science Officer, Foundation for Angelman Syndrome Therapeutics
Diane Berry, Vice President, Global Health Policy And Government Affair, Sarepta Therapeutics
Betsy Bogard, Programme Leader, Early Development, Avrobio
Luc Boileau, Chairman And Chief Executive Officer, INESSS
Vanessa Boulanger, Director Of Research Programs, NORD
Paula Boultbee, Chief Commercial Officer, Oncopeptides AB
Alfred Boyle, Senior Vice President Technical Operations, Alnylam Pharmaceuticals
Michael Bozik, President And Chief Executive Officer, Knopp Biosciences
Todd Brady, Chief Executive Officer, Aldeyra Therapeutics
Troyen Brennan, Executive Vice President And Chief Medical Officer, CVS Health
Jennifer Bright, Executive Director, Innovation And Value Initiative
Brian Bronk, Head Of Business Development, Rare Diseases & Rare Blood Disorders, Global Business Development & Licensing, Sanofi
Philip J Brooks, Program Director, National Center For Advancing Translational Sciences - Ncats, National Institutes of Health (NIH)
Bert Bruce, Vice President, Rare Disease Commercial Development, Pfizer
Michael Brudno, Scientific Director Of Centre For Computational Medicine, Hospital for Sick Children
Wilson Bryan, Director, Office Of Tissues And Advanced Therapies, Cber, FDA
Chuck Bucklar, Group Vice President, Commercial Operations North America, BioMarin Pharmaceutical Inc.
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Rob Burley, Director Of Campaigns, Care And Support, The Muscular Dystrophy U.K.
Lauren Bylsma, Senior Epidemiologist, EpidStrategies, A Division of ToxStrategies
Mindy Cameron, Advocacy Director, Little Hercules Foundation
Julia Campbell, VP, Client Strategies and Services, Durbin
Catherine Cancian, VP Pharmaceutical Operations, GenSight Biologics
Casey Case, Senior Vice President Of Research And Development, 4D Molecular Therapeutics
Alan Cash, Chief Executive Officer And Co-Founder, MetVital
Chelsea Catsburg, Engagement Manager, BluePrint Orphan
Rick Chapman, Director Of Health Economics, ICER
Lynsey Chediak, Project Lead, Precision Medicine, World Economic Forum
Alexander Cole, Executive Director, Global Head Epidemiology, Alexion
Alexander Cole, Executive Director, Global Head Epidemiology, Alexion
Ellen Coleman, President And Chief Executive Officer, VOZ Advisors
Rob Colenso, Senior Director, Product Management, rareLife solutions
Brett Cook, Senior Associate, F-Prime Capital Partners
Gavin Corcoran, Chief Research And Development Officer, Axovant Sciences
Shelby Corman, Executive Director and Lead, Real-World Evidence/Data Analytics Center of Excellence, OPEN Health
Christina Coughlin, Chief Medical Officer, Rubius Therapeutics
Benoit Coulombe, Founder, Professor and Director Of Translational Proteomics At The Montreal Clinical Research Institute, Open for Rare
Anne Cropp, Chief Scientific Officer, Early Access Care
Emily Crossley, Co-Founder, Duchenne U.K.
John Crowley, Chief Executive Officer, Amicus Therapeutics Inc
Pam Crowley Andrews, Co-Founder And Executive Director, Firefly Fund
Daniel Curran, Head, Rare Diseases Therapeutic Area Unit, Takeda
Omar Dabbous, Vice President, Health Economics And Outcomes Research, AveXis
Yong Dai, Chief Technology Officer, Prevail Therapeutics
Olivier Danos, Chief Scientific Officer, Regenxbio Inc
Santanu Das, Managing Director, Huron Consulting Group
Sarah Dash, Chief Executive Officer, Alliance For Health Policy
Nach Dave’, Vice President, Development Strategy, Premier Research
Khrystal K Davis, President, Texas Rare Alliance
Stratos Davlos, CTO & SVP Managing Director, Innoplexus
Tom Defay, Senior Director, Research And Development, Strategy And Alliance Management, Alexion Pharmaceuticals
Ebrahim S Delpassand, Chairman And Chief Executive Officer, RadioMedix Inc.
Eelko Den Breejen, Associate Director, Market Access, Biogen
Paulla Dennis, Director, Rare Disease and Pediatrics,, Covance
Frederick Derosier, Executive Director, Rare Diseases, Covance
Sheila Diamond, Scientific Business Development, Medidata, a Dassault Systèmes company
Scott Dorfman, CEO, Odylia Therapeutics
Debbie Drell, Director Of Membership, National Organization for Rare Disorders (NORD)
Andrew Ecob, Vice President Of Real World Evidence Strategy, Parexel
Sean Ekins, Founder And Chief Executive Officer, Collaborations Pharmaceuticals
Jacqueline Erdo, Senior Manager, Policy & Advocacy,, Cystic Fibrosis Foundation
Rafael Escandon, Vice President Of Development Operations, BridgeBio-Gene Therapy
Lisa Feng, Senior Director, Policy And Advocacy, Cystic Fibrosis Foundation
Lewis Fermaglich, Medical Advisor, Office of Orphan Products Development,, FDA
Vivian Fernandez, Director Of Patient Advocacy, Regenxbio Inc
Emily Fields, Senior Manager, Patient Advocacy, bluebird bio
Alison Finger, Chief Commercial Officer, bluebird bio
Amanda Finlayson, Therapeutic Strategy Lead, ClinEdge
Dakota Fisher-Vance, Patient Advocacy Manager, Horizon Therapeutics
Nasha Fitter, Chief Executive Officer And Head Of Research, FOXG1 Research Foundation
Matt Flesch, Vice President Of Communications And Patient Advocacy, Horizon Therapeutics
Kelly Folkers, Senior Research Associate, Division Of Medical Ethics,, NYU Langone Medical Center
Chad Forinash, Senior Director, Pharmacy And Clinical Services, PharmaCord
Romina Foster-Bonds, Programs Director, CureDuchenne
Danielle Friend, Director Of Science And Regulatory Affairs, Biotechnology Industry Organization
Jon Fryzek, Practice Director, Epidemiology, EpidStrategies, A Division of ToxStrategies
Andrea Furia-Helms, Director, Patient Affairs Staff, U.S. Food and Drug Administration
Pat Furlong, Founding President And Chief Executive Officer, Parent Project Muscular Dystrophy
Kamilla Gaitova, Head Of Center For Health Economics And Health Technology Assessment, Republican Center for Health Development, Kazakhstan
Mark Galbraith, Head Of Quality Control And Analytical Sciences, Spark Therapeutics
Todd Galles, VP, US Business Development, EAPs, Durbin
Aprel Gandy, Global Strategic Program Manager – Health & Life Science, Travel Leaders Corporate
Bobby Gaspar, Chief Executive Officer, Orchard Therapeutics
Pamela Gavin, Chief Strategy Officer, National Organization for Rare Disorders (NORD)
Beverly Ginsbury, Managing Director, Huron Consulting Group
Sarah Glass, Senior Director, Translational Medicine, Head of Rare Diseases, Parexel
Jose F. Gomez, SVP, Global Market Access & Value, Avrobio
Peter Goodhand, Chief Executive Officer, Global Alliance for Genomics & Health
Barbara Goodman, President And Chief Operating Officer, Cures Within Reach
Alice Chen Grady, Program Officer, Office of Rare Diseases Research, NIH/NCATS
Joana Granado, External Innovation Director, Actelion - A Janssen Pharmaceutical Company of Johnson&Johnson
Amy Gray, Chief Executive Officer, Charcot-Marie-Tooth Association
Scott Gray, CEO, Clincierge
Bernard Grimm, Director, EuropaBio
Mike Hale, Vice President And Chief Statistical Scientist, Takeda Pharmaceuticals
Laura Hameed, Executive Director, The Columbus Children’s Foundation
Marianne Hamilton Lopez, Research Director, Duke Margolis Center for Health Policy
Michael Hanley, Chief Commercial Officer, Aeglea BioTherapeutics
Patrick Haslett, Executive Director Of Clinical Research And Biology, Alnylam Pharmaceuticals
Andrea Haworth, Head of Clinical Services, Congenica
Robert Haynes, Product Development lead, Regenxbio
Jennifer Helfer, Director, Global Patient Advocacy Lead, bluebird bio
Rachele Hendricks-Sturrup, Health Policy Lead, Future of Privacy Forum
Arthur Herman, Fellow, World Economic Forum, Precision Medicine Portfolio, Principal Strategic Consultant, Kaiser Permanente
Ines Hernando, Director, EURORDIS
Sharon Hesterlee, Executive Vice President, Chief Research Officer, Muscular Dystrophy Association
Claudia Hirawat, Executive Chairman, VOZ Advisors
Andrew Hobbs, Managing Director, Huron Consulting Group
Melissa Hogan, Rare Disease Parent/Advocate, CEO, Doulots
Andy Holt, Vice President Of Business Development and Manufacturing, Asklepios BioPharmaceutical Inc
Kui Huang, Rare Disease Epidemiology Lead Strategist, Pfizer
Kevin Huang, President, Chinese Organization for Rare Disorders
Raymond Huml, Vice President of Medical and Scientific Strategy, Head, Health’s Rare Disease Consortium, Syneos Health
Adam Hutchings, Director, Dolon
Rachelle Jacques, Chief Executive Officer, Enzyvant
Gavin Jones, Director of Rare Disease, OPEN Health
Emil Kakkis, Chief Executive Officer, Ultragenyx Pharmaceutical
Sujay Kango, Chief Commercial Officer, Acceleron Pharma
Rashida Karmali, CEO, Tactical Therapeutics Inc
Vikram Karnani, Executive Vice President, Chief Commercial Officer, Horizon Therapeutics
Reena Kartha, Associate Director, Center for Orphan Drugs Research, University of Minnesota, Director of Research Programs, IndoUSrare
Thomas Kassberg, Chief Business Officer And Executive Vice President, Ultragenyx Pharmaceutical
Ken Kengatharan, Managing Partner, Atheneos Ventures And Chief Executive Officer, Atheneos Ventures
Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases
Uday Khire, Chief Executive Officer, AlloMek
Sean Khozin, Global Head Of Data Strategy, Johnson & Johnson
Maya Khurana, Director, Huron Consulting Group
Therese Kinsella, Founder And Chief Scientific Officer, ATXA Therapeutics
Terri Klein, President And Chief Executive Officer, National M.P.S. Society
Daniel Knecht, Vice President Of Health Strategy And Innovation, CVS Health
Prashant Kohli, Vice President Commercial Operations, Grace Therapeutics
Jonathan Kornstein, Executive Director, Program Strategy, Premier Research
Mark Kroes, Chief Executive Officer, Global Data Support
Akshay Kumar, Partner, Partners4Access
Salvatore La Rosa, Chief Scientific Officer, Children's Tumor Foundation
Steven Laffoon, President, Wylder Nation
Genevieve Laforat, Vice President, Clinical Development, Aspa Therapeutics/BridgeBio Gene Therapy
Tom Lambdin, Executive Director, Ben's Friends
Janet Lynch Lambert, Chief Executive Officer, Alliance for Regenerative Medicine
Jim Lang, Chief Executive Officer, EVERSANA
David Lapidus, President, Lapidus Data
Leanne Larson, Corporate Vice President and WW Head, Real-World Evidence, Parexel
Yann Le Cam, Chief Executive Officer, EURORDIS
Kimberly Leblanc, Associate Director Of Research Operations Undiagnosed Diseases Network Coordinating Center, Harvard Medical School
Joseph Lee, Executive Director, PTC Therapeutics
Michael Lehmicke, Director, Science and Industry Affairs, Alliance for Regenerative Medicine
Clement Leong, Chief Executive Officer And Managing Director, Stamford Pharmaceuticals
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Paul Levesque, Global President, Rare Disease, Pfizer
Jeremy Levin, Chairman and Chief Executive Officer, Chairman, BIO, Ovid Therapeutics
Edmund Lim, Abc, We CARE Journey
Marius George Linguraru, Principal Investigator at Children’s National Health System, Professor of Radiology, Pediatrics and Biomedical Engineering, The George Washington University
Donald Lo, Director, Therapeutic Development Branch, Division Of Pre-Clinical Innovation, National Center for Advancing Translational Sciences - NCATS
Robert Lodder, President, Biospherics
Brian Loew, CEO, Inspire
Robert Long, Executive Director, Uplifting Athletes
Jarrod Longcor, Chief Business Officer, Cellectar Biosciences Inc
Sam Lucas, SVP, Expanded Access Programs, Durbin
Wolfram Lux, Senior Director, Simon-Kucher & Partners
Pamela Mace, President, Fibromuscular Dysplasia Society of America
Sandy Macrae, President And Chief Executive Officer, Sangamo Therapeutics
Matthew Majewski, Vice President, Charles River Associates
Craig Malzahn, VP of Manufacturing and Supply, REGENX Bioscience
Peter Marks, Director, Center For Biologics Evaluation And Research (CBER), U.S. Food and Drug Administration
Sebastien Martel, Global Head of Rare Diseases, Sanofi
Paolo Martini, Chief Scientific Officer, Rare Diseases, Moderna Therapeutics
Allison May Rosen, Representative, Firefly Fund
Janet Maynard, Director, Office Of Orphan Products Development, Food And Drug Administration, U.S. Food and Drug Administration
Mary Mcgowan, Executive Director, The Myositis Association
Amy Mckee, Vice President, Regulatory, Parexel Consulting, Parexel International
Jennifer Mcmahon, Principal, Seroba Life Sciences
Jenn Mcnary, Founder, One Rare
Eileen Mcneill, Programme Manager - Disease Foundations, Oxford University Structural Genomics Consortium
Kirsten Mease, Managing Scientist, ToxStrategies
Tracy Meffen, VP, Quality & Regulatory Affairs,, Genevant Sciences
Pooja Merchant, Head Of Patient Partnership, Engagement And Oncology, Bayer US LLC
Parag Meswani, SVP, Commercial, Axovant Gene Therapies
Annastasiah Mudiwa Mhaka, Co-Founder, Convenor, President, Alliance for Artificial Intelligence in Healthcare
Sheila Mikhail, President And Co-Founder, Asklepios BioPharmaceutical Inc
Randy Milby, Chief Executive Officer, Hillstream Biopharma
Timothy Miller, Co-Founder, President And Chief Scientific Officer, Abeona Therapeutics
Debra Miller, CEO & Founder, CureDuchenne
James Miskin, Chief Technical Officer, Oxford Biomedica
Hubert Misztela, Machine Learning Expert At Novartis, Lecturer At Dublin Business School, Novartis
Ali Mohamadi, Executive Director, BioMarin Pharmaceutical Inc.
Samarendra Mohanty, Founder And President, NanoScope Technologies
Michael Murphy, Chief Medical & Scientific Officer, Worldwide Clinical Trials
Michelle Muscat, Co-Founder And President, National Alliance for Rare Diseases Support - Malta
Nuriya Musina, Head Of Development, Federal State Budgetary Institution, The Center For Healthcare Quality Assessme, Ministry of Health Russian Federation
Joseph Musumeci, President, BluePrint Orphan
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Lauren Neighbours, VP, Regulatory Affairs & Program Management, Optum
Brian Newkirk, Market Access Director, Alnylam Pharmaceuticals
Jay Newman, Senior Vice President and General Manager, Head Of Us Commercial, Spark Therapeutics
Scott Nickerson, Senior Vice President, Global Quality, Moderna Therapeutics
Jan Nielsen, Division President, Patient Solutions, AssistRx Patient Solutions
Yukiko Nishimura, President, ASrid Japan
Neena Nizar, President, The Jansens Foundation
Sara Nochur, Senior Vice President Regulatory Affairs, Alnylam Pharmaceuticals
Mukund Nori, Director, Medical Affairs & Principal Med, rareLife solutions
Wolfram Nothaft, Chief Medical Officer, Takeda
Lynn O'Connor Vos, Chief Executive Officer, Muscular Dystrophy Association
Daniel O'Mahony, Partner, Seroba Life Sciences
Lianna Orlando, Senior Director Of Research, CureDuchenne
Nawal Ouzren, Chief Executive Officer, Sensorion Pharma
Arrigo Paciello, Assessor, AIFA
Cindy Padgett, Vice President, PharmaCord
Nick Page, Chief Operations Officer, Oxford Biomedica
Palani Palaniappan, CTO, Aruvant
Jim Palma, Executive Director, TargetCancer Foundation
Francis Pang, Vice President Global Market Access, Orchard Therapeutics
Art Pappas, Managing Partner, Pappas Capital
Bhash Parasuraman, Vice President Of Business Unit Lead, Rare Disease, Patient And Health Impact, Pfizer
Andrew Parece, Vice President, Charles River Associates
Anne Pariser, Director, Office Of Rare Diseases Research, National Center For Advancing Translational Sciences - Ncats, National Institutes of Health (NIH)
Detlev Parow, Head Pharmaceutical Department, D.A.K.
Linn Parrish, Global Patient & Scientific Affairs, Chief Medical Office,, Takeda
Doug Paul, Vice President And Partner, MME
Peter Payne, Vice President, Head of the Digital Research Network, Optum
Steven Peskin, Associate Clinical Professor Of Medicine, Rutgers Rwj Medical School, Executive Medical Director Population Health And Transform, Horizon Blue Cross Blue Shield - New Jersey
Dmitry Petrov, Head Of Medical Writing And Pharmacovigilance, ICRC-Weyer GmbH
Areejit Phukan, Director, Analytics And Forecasting, Insmed Inc
Andres Pichon-Riviere, Executive Director Of The Institute For Clinical Effectiveness And Health Policy (Iecs), Director Of The Health Technology, University Of Buenos Aires
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Sarah Pitluck, Head, Global Pricing And Reimbursement, Spark Therapeutics
Leslie Powell, Director Of Policy And Advocacy, Cystic Fibrosis Foundation
Mayo Pujols, Vice President, Head Of Global Cell And Gene Technical Development And Manufacturing, Novartis
Anthony Quinn, President And Chief Executive Officer, Aeglea BioTherapeutics
Harsha Rajasimha, Founder And Chairman, IndoUSrare
Shankar Ramaswamy, Chief Business Officer, Axovant
Kyle Rasbach, Partner, Pappas Ventures
Karlyne Reilly, Senior Associate Scientist And Section Head, National Cancer Institute
Frederic Revah, Chief Executive Officer, Genethon
John Reynders, Vice President, Data Sciences, Genomics, And Bioinformatics, Alexion Pharmaceticals
Marisa Ricci, Vice President Patient Diagnosis Programs And U.S. Field Medical Engagement, Ultragenyx Pharmaceutical
Dara Richardson-Heron, Chief Patient Officer, Pfizer
Will Richmond, Lead, Value And Access, Sanofi Genzyme
Trevor Richter, Director, Common Drug Review And Optimal Use, CADTH
Shawn Ritchie, Chief Executive Officer, Med-Life Discoveries
Juan Roman, Head Of Market Access And Pricing, Acceleron Pharmaceuticals, Inc.
Kieran Rooney, Vice President, Strategic Alliances And Licensing, Amryt Pharmaceuticals
Luke Rosen, Vice President, Accelerated Development & Patient Engagement, Ovid Therapeutics
Ruth Rostron, Vice President Of Project Management, Inceptua Medicines Access
Seth Rotberg, Co Founder And President, Our Odyssey
John Rother, Chief Executive Officer, National Coalition On Health Care
Delphine Roulland, Director Government Affairs And Public Policy, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Kacper Rucinski, Executive Committee Member, SMA Europe
Christopher Rudolf, Founder And Chief Executive Officer, volv global
David Russell, Head Of External Innovation, Actelion-Janssen
Leo Russo, Senior Director, Epidemiology Worldwide Safety And Regulatory, Pfizer
Susan S, Advocate, Patient Advocate
Peter Saltonstall, Chief Executive Officer, National Organization for Rare Disorders (NORD)
Abby Sandler, Executive Director, Mypart, Center For Cancer Research,, National Institutes of Health
Scott Schliebner, SVP, Scientific Affairs, PRA Health Sciences
Sophie Schmitz, Managing Partner, Partners4Access
Dana Schoknecht, Life Sciences Manager, MUV People
Jeffrey Schwartz, Managing Director, Bain Capital Life Sciences
Denise Scots Knight, Chief Executive Officer And Co-Founder, Mereo BioPharma
Jessica Scott, Head of R&D Patient Engagement Office,, Takeda Pharmaceuticals
Joanna Segieth, CEO, Biosynetix
Simone Seiter, Partner, Simon-Kucher & Partners
Jim Shaffer, Cbo, Eiger Biopharmaceuticals
Lesha Shah, Co-Chair, Pediatric Gene Therapy And Medical Ethics Working Group, Assistant Professor Of Psychiatry, Icahn School Of Medicine, The Mount Sinai Hospital
Avinash Shanbhag, Director, Nationwide Health Information Network Division, U.S. Department of Health & Human Services
Nataliya Shandarovska, patient, patient advocate, senior staff nurse, National Alliance for Rare Diseases Support - Malta
Panna Sharma, President And Chief Executive Officer, Lantern Pharma
Adam Shaywitz, Chief Medical Officer, Rare Disease Drug Development, BridgeBio Pharma
Rachel Sher, Vice President Policy And Regulatory Affairs, NORD
Alex Sherman, Director, Center For Innovation And Bioinformatics, Harvard Medical School
Gerard Short, svp medical science, Freeline Therapeutics
Oodaye Shukla, Chief Data Officer, HVH Precision Analytics, now EVERSANA
Anna Shurshalina, Global Safety Lead, Safety Physician, Oncology. Benefit Risk Management, Pharmacovigilance, Bayer Pharmaceuticals
Alison Skrinar, Vice President, Clinical Outcomes Research And Evaluation, Ultragenyx Pharmaceutical
Andrew Slugg, Senior Vice President Of Regulatory Affairs, Alnylam Pharmaceuticals
Kristin Smedley, President, Curing Retinal Blindness Foundation
Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer
Peter Snyder, Medical and Scientific Publications, rareLife solutions
Nancy Spinner, Chief of the Division of Genomic Diagnostics, The Children's Hospital of Philadelphia
Meagan Spychala, Assistant Vice President Of Patient Engagement And Program Strategy, Rho, Inc
Alicia Staley, Senior Director, Patient Engagement, Medidata, a Dassault Systèmes company
Cornell Stamoran, Vice President of Corporate Strategy, Catalent Pharma Solutions
Kim Stephens, President, Project Alive
Dean Suhr, President, MLD Foundation
Jamie Sullivan, Director Of Public Policy, EveryLife Foundation for Rare Diseases
Marshall Summar, Division Chief Of Genetics And Metabolism, Children's National Medical Center
Weiyong Sun, Senior Director, Specialty Medicine Search, Evaluation And Global Business Development, Daiichi Sankyo Co Ltd
Thayer Surette, Deputy Director, Partnership to Improve Patient Care (PIPC)
Heather Swech, Senior Director, Patient Discovery, Alnylam Pharmaceuticals
Stephanie Tagliatela, Co-Founder And Chief Scientific Officer, Encoded Therapeutics
Magali Taiel, CMO, GenSight Biologics
Jason Tardio, Chief Commercial Officer, Ovid Therapeutics
Jeffrey Terkowitz, VP, Product, Inspire
Ulrich Thienel, Chief Executive Officer, ReAlta Life Sciences
Jan Thirkettle, Chief Development Officer, Freeline Therapeutics
Becky Thompson, Director Integrated Solutions, Parexel
Dan Tierno, Strategic Implementation Manager, Global Data Sciences And Analytics, Bayer US LLC
Cynthia Tifft, Deputy Clinical Director, Office Of The Clinical Director, National Human Genome Research, National Human Genome Research Institute
Brigette Tippin Davis, Senior Vice President, R&D, Ambry Genetics
Vladimir Tomov, Chairman, National Alliance of People with Rare Diseases - Bulgaria
Ngeh Toyang, Chief Executive Officer, Flavocure Biotech
Sara Traigle Van Geertruyden, Executive Director, Partnership to Improve Patient Care (PIPC)
Tim Turnham, Vice President, VOZ Advisors
Sheela Upadhyaya, Rare Disease Expert, National Institute for Health and Care Excellence
Evert Jan Van Lente, Director Eu-Affairs, AOK Bundesverdand
Thomas VanCott, Chief Technology Strategy Officer at Catalent Biologics, Catalent Cell & Gene Therapy
Carole Spangler Vaughn, Chief Executive Officer, Emtora Biosciences
Jodie Vento, Chair, Access Committee, National Society Of Genetic Counselors, Manager, Center For Rare Disease Therapy, Childrens Hospital of Pittsburgh
Terry Jo Vetters Bichell, Founder And Director, COMBINEDBrain
Craig Wakeford, Director, Global Value And Access, Biogen
Kim Warren, Head Of Operations, Avrobio
Melissa Wasserstein, Chief, Division Of Pediatric Genetic Medicine, Department Of Pediatrics,, Montefiore Medical Center
Christina Waters, Chief Executive Officer And Founder, RARE Science
Allison Watson, Co founder/Secretary, Ring20 Research and Support UK
Monica Weldon, President/CEO, Bridge The Gap Syngap Education And Research Foundation
Bjorn Wester, Global Client Services Manager, Clincierge
Samuel Agyei Wiafe, Executive Director, Rare Disease Ghana Initiative
Terry Wilcox, Co-Founder And Executive Director, Patients Rising & Patients Rising
Laurie Witherwax, Sr Vice President, Site Activation, Worldwide Clinical Trials
Durhane Wong-Rieger, President And Chief Executive Officer, Canadian Organization For Rare Disorders
Marcie Wood, Senior Managing Scientist, Practice Director, Biopharmaceutical/Pharmaceutical, ToxStrategies
Janet Woodcock, Director Of Drug Evaluation And Research Center, Food and Drug Administration (FDA)
Jonathan Woodring, Executive Vice President And General Manager, IPM.ai
Laura Wuerth, Vice President, rareLife solutions
Loukas Xaplanteris, Director Eu+ Value And Market Acces, Biogen
William Xiang, Director, Strategy And Operations, XW Laboratories
Richard R Yang, Chief Executive Officer And Founder, Reflection Biotechnologies
Zheng Yang, Head Of Technology And Data Innovation, Customer Value, Boehringer Ingelheim
Dimitar Yonchev, Patient Advocate Representative, Pro Retina Deutschland e.V.
David Young, Chief Executive Officer, Processa Pharmaceuticals, Inc.
Timothy Yu, Attending Physician, Investigator, Division Of Genetics And Genomics, Boston Children's Hospital
Wyatt Yue, Principal Investigator, Associate Professor, Lead Scientist, Rare Disease Research, Oxford University Structural Genomics Consortium
Martin Zagari, Vice President Global Health Economics, Amgen Inc
Shuyang Zhang, Department Of Cardiology, Peking Union Medical College
Ran Zheng, Chief Technology Officer, Orchard Therapeutics
Sameer Zuberi, Consultant Paediatric Neurologist, President, European Paediatric Neurology Society, Royal Hospital for Children,, National Health Service
Organiser
